Managing Lung Fibrosis in Systemic Sclerosis Patients

Robert F. Spiera, MD


June 18, 2020

Systemic sclerosis, also known as scleroderma, is generally considered an autoimmune disorder characterized by fibrosis and buildup of scar tissue in the skin and internal organs, including the musculoskeletal system, lungs, kidney, heart, gastrointestinal tract, and peripheral circulation.

Studies have shown that damage to the lungs, together with associated impairment of lung function, is the leading cause of death in people with systemic sclerosis.

Dr Robert Spiera, director of the vasculitis and scleroderma program at the Hospital for Special Surgery, discusses the role of lung fibrosis in people with systemic sclerosis, and how proper assessment and treatment can optimize patient outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.